Clinical and Experimental Dermatology最新文献

{"title":"Lichen planus following COVID-19 vaccination: a narrative review.","authors":"Michela D'Agostino, Fabrizio Martora, Matteo Megna, Maddalena Napolitano, Luca Potestio","doi":"10.1093/ced/llae356","DOIUrl":"10.1093/ced/llae356","url":null,"abstract":"<p><p>Lichen planus (LP) is an inflammatory disease that afflicts the skin, mucous membranes and cutaneous appendages. Moreover, LP represents a prototype of lichenoid dermatosis, being characterized by the presence of a dense dermal cell infiltrate. Although most cases of LP are idiopathic, infectious and drug-related factors must also be considered in the aetiology. In this context, the occurrence of LP and lichenoid drug eruptions following different types of vaccination is a possible event. Therefore, the aim of our review is to provide a broad perspective to clinicians by analysing the current literature of cases of LP and lichenoid eruptions following COVID-19 vaccination, and also investigating the possible pathogenetic mechanisms underlying this phenomenon. In total, 61 cases of LP and lichenoid eruption following COVID-19 vaccination have been collected. However, the number of cases of LP and lichenoid drug eruption is extremely low compared with the number of vaccines administered overall, suggesting that the risk of LP and lichenoid eruption following COVID-19 vaccination is extremely low. Certainly, further studies are desirable to identify the population most at risk and the possibility of taking preventive measures.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"260-266"},"PeriodicalIF":3.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sudden pruritic eruption in a patient with vulvar cancer.","authors":"Laurine Batut, Elise Sauvain, Clothilde Canard, Marine Fontaine, Estelle Vigneau, Manuelle Viguier","doi":"10.1093/ced/llae422","DOIUrl":"10.1093/ced/llae422","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"484-486"},"PeriodicalIF":3.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory papulonodular mucinosis successfully treated with tofacitinib.","authors":"Si-Yu Luo, Sheng Fang","doi":"10.1093/ced/llae438","DOIUrl":"10.1093/ced/llae438","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"448-450"},"PeriodicalIF":3.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Goldfinger: a case of a patient with metal tattooing mimicking recurrent melanoma.","authors":"Liana Victory, Claire Quigley, Jane Doheny, Aoibheann Flynn, Shirley Potter, Fergal J Moloney","doi":"10.1093/ced/llae370","DOIUrl":"10.1093/ced/llae370","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"491-493"},"PeriodicalIF":3.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of STAT3, IL27p28 and IL12p35 is deregulated and linked to autoimmune markers in chronic spontaneous urticaria.","authors":"Sahar Rastgoo, Mojgan Mohammadi, Marcus Maurer, Mahdi Atabaki, Jalil Tavakkol-Afshari, Maryam Khoshkhui","doi":"10.1093/ced/llae319","DOIUrl":"10.1093/ced/llae319","url":null,"abstract":"<p><strong>Background: </strong>Chronic spontaneous urticaria (CSU) is a common inflammatory disorder characterized by weals, angio-oedema, or both, for more than 6 weeks. Autoimmunity is held to be one of the most frequent causes, but little is known about the expression and relevance of autoimmunity-driving genes in CSU, such as STAT3, STAT1, IL27p28 (IL30) and IL12p35 (IL12A).</p><p><strong>Objectives: </strong>To investigate patients with CSU and the expression of STAT3, STAT1, IL27p28 and IL12p35, and possible links to clinical features.</p><p><strong>Methods: </strong>We enrolled 26 patients with CSU and 19 healthy controls (HCs) and determined their expression levels of STAT3, STAT1, IL27p28 and IL12p35 by quantitative real-time polymerase chain reaction. Patients were assessed for total IgE and IgG-anti-thyroid peroxidase (TPO), markers of autoimmune CSU.</p><p><strong>Results: </strong>Patients with CSU showed significantly higher expression of STAT3 but not STAT1: 17 (65%) and 10 (38%) of the 26 had elevated STAT3 expression and STAT3/STAT1 ratios, respectively, as compared with only 1 (5%) of the 19 HCs. High STAT3 expression and STAT3/STAT1 ratios were linked to low IgE and elevated IgG-anti-TPO. As compared with HCs, patients with CSU had markedly lower and correlated IL27p28 and IL12p35 mRNA expression levels. Low IL27p28 and IL12p35 expression levels were linked to higher STAT3/STAT1 ratios and low IgE.</p><p><strong>Conclusions: </strong>STAT3 upregulation and higher STAT3/STAT1 ratios, along with IL27p28 and IL12p35 downregulation, clusters with features of autoimmune CSU. The role of STAT3 as a potential pathogenic driver of autoimmune CSU and target of treatment should be explored further.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"357-364"},"PeriodicalIF":3.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141896911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease.","authors":"Niamh Kearney, Xin Chen, Yingtao Bi, Kinjal Hew, Kathleen M Smith, Brian Kirby","doi":"10.1093/ced/llae324","DOIUrl":"10.1093/ced/llae324","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) is associated with increased cardiovascular disease (CVD) risk. Systemic immune inflammation index (SII), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and monocyte/lymphocyte ratio (MLR) are biomarkers of systemic inflammation and CVD. One small study identified a lower NLR and PLR in patients treated with adalimumab (ADA).</p><p><strong>Objectives: </strong>To assess changes in SII, NLR, PLR and MLR in a larger cohort and to evaluate their association with disease severity and treatment response.</p><p><strong>Methods: </strong>This was a post hoc analysis of PIONEER I (ClinicalTrials.gov ID: NCT01468207) and PIONEER II (ClinicalTrials.gov ID: NCT01468233), two phase III randomized placebo-controlled clinical trials of ADA for HS. SII, NLR, PLR and MLR were log10-transformed and a linear mixed model was used to estimate the treatment effect.</p><p><strong>Results: </strong>SII, NLR, PLR and MLR decreased from baseline levels with ADA treatment by week 12, when the primary response endpoint was assessed. Significant changes first appeared at week 4 and were maintained to week 36. In contrast, no significant changes were observed in placebo-treated patients. In patients re-randomized at week 12 from placebo to ADA, SII, NLR, PLR and MLR also reduced within 4 weeks. In patients re-randomized from ADA to placebo, these biomarkers returned to baseline by week 36. In addition, SII, NLR and PLR correlated with draining fistula count (r = 0.26-0.43, P < 0.001). ADA nonresponders in PIONEER I had a higher SII, NLR and PLR at baseline and week 12, but this change did not achieve statistical significance when draining fistulae were adjusted for.</p><p><strong>Conclusions: </strong>Treatment of patients with HS with ADA resulted in rapid sustained reduction in systemic inflammation, measured by the biomarkers SII, NLR, PLR and MLR, which correlate with CVD risk. SII, NLR and PLR may predict ADA response, although this may be dependent on their interaction with the number of draining fistulae.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"339-347"},"PeriodicalIF":3.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revealing patient characteristics and treatment outcomes among ultra-long users of biologics for psoriasis.","authors":"Nikki F T Henckens, Marisol E Otero, Juul M P A van den Reek, Elke M G J de Jong","doi":"10.1093/ced/llae333","DOIUrl":"10.1093/ced/llae333","url":null,"abstract":"<p><strong>Background: </strong>Biologics are effective for the treatment of psoriasis, but little is known regarding patients treated with one biologic for an 'ultra-long' duration.</p><p><strong>Objectives: </strong>To explore the prevalence, patient and treatment characteristics, and treatment outcomes of ultra-long users of biologics for psoriasis.</p><p><strong>Methods: </strong>Data for patients with psoriasis who had received continuous treatment with the same biologic for ≥ 10 years were collected from the prospective, multicentre BioCAPTURE cohort. Baseline characteristics of these ultra-long users were determined and compared with the total BioCAPTURE population. The proportion of patients using concomitant systemic treatment and receiving dose adjustments, the trajectory of Psoriasis Area and Severity Index scores and drug survival rates beyond 10 years were also analysed.</p><p><strong>Results: </strong>Among the BioCAPTURE cohort, 30.5% of patients with the potential to achieve a treatment episode of ≥ 10 years reached this treatment duration. These patients were treated with ustekinumab, etanercept, adalimumab and infliximab. The proportion of ultra-long users was highest for ustekinumab (37.1%). The ultra-long user cohort had a slightly longer disease duration at registry entry, and a higher proportion of men and patients diagnosed with psoriatic arthritis (PsA) than the total BioCAPTURE population. Among the cohort, 69.5% of patients had at least one comorbidity and 66.1% used no additional systemic antipsoriatic treatment. Dose adjustments were often applied, varying from dose escalation (29.7%), dose reduction (40.7%) or both (13.6%); only 16.1% of patients consistently used the standard dose throughout their treatment. The median PASI score for ultra-long users from month 6 onwards was consistently < 3, with only a small proportion achieving complete clearance of their psoriasis (3.9-13.7% at the various timepoints). Drug survival analysis beyond 10 years showed that 62.3% of patients were still being treated with the same biologic after 15 years.</p><p><strong>Conclusions: </strong>Ultra-long use of the same biologic in patients with psoriasis was common in real-world practice but varied between biologics. The median PASI score was around 2.5 throughout the 10-year treatment course; complete clearance was often not achieved. Remarkably, ultra-long use was also recorded in patients with multiple comorbidities (including PsA). Dose adjustments of the biologic were applied in the majority of patients. These results provide clinicians with important evidence on ultra-long treatment with biologics, thereby improving psoriasis care and the management of treatment expectations.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"348-356"},"PeriodicalIF":3.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of nonpharmacological treatment options for skin picking disorder.","authors":"Harrison Loftus, Caroline Cassidy, Lisa Mun, Mohammad Jafferany","doi":"10.1093/ced/llae366","DOIUrl":"10.1093/ced/llae366","url":null,"abstract":"<p><p>Skin picking disorder (SPD) is a well-described neuropsychiatric disorder that causes severe stress and impairment. However, there is no clear protocol for treating patients, and only a relatively small body of literature evaluating treatment approaches. This review aims to summarize and compare recent publications and provide an up-to-date guide of current nonpharmacological treatments for SPD. A literature review was conducted on all nonpharmacological SPD treatment studies published between 2017 and 2023 using PubMed, CINAHL Plus with Full Text (EBSCO) and Scopus. Search terms included 'skin picking', 'excoriation', 'psychiatry', 'treatment' and 'psychodermatology'. Studies including SPD within other body-focused repetitive behaviours, studies using pharmacological agents, and studies not available in English were excluded. A minimum of two authors screened each abstract to assess for inclusion while being blinded to minimize bias. Eleven studies (2068 participants) were included, with a variety of study designs including feasibility, randomized controlled trial, longitudinal cohort, multiple-baseline experimental, naturalistic trial, and controlled single-case design with multiple-baseline studies. The treatments include cognitive behavioural therapy (CBT), acceptance and commitment therapy (ACT), ACT-enhanced group behavioural therapy (AE-GBT), ACT-informed exposure therapy, group therapy, psychotherapy, repetitive transcranial magnetic stimulation, online self-help modules, and expressive writing. Studies implementing CBT, habit reversal therapy, AE-GBT, online self-help modules, and expressive writing demonstrated the best results in treating SPD. Several studies achieved significant outcomes for participants with SPD, confirming the usefulness of nonpharmacological treatment in SPD. Based on our results, CBT, AE-GBT, online self-help modules and expressive writing appear to be the most effective in treating SPD. Additionally, most of these treatment modalities can be tailored to meet patient-specific needs. Some limitations of the studies include small sample sizes, lack of control groups and randomization, limited long-term follow-up data and lack of gender variability.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"299-306"},"PeriodicalIF":3.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-specific presentation and outcome of drug reaction with eosinophilia and systemic symptoms (DRESS) in children: a scoping review.","authors":"Frances St George-Hyslop, Nicole Cherepacha, Bindiya Chugani, Yousef Alabdeen, Luis Fernando Sanchez-Espino, Quenby Mahood, Cathryn Sibbald, Ruud H J Verstegen","doi":"10.1093/ced/llae418","DOIUrl":"10.1093/ced/llae418","url":null,"abstract":"<p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe adverse drug reaction with significant variation between patients concerning presenting symptoms and disease severity. Under the hypothesis that the clinical presentation of DRESS is drug specific, we performed a scoping review and identified 644 cases of paediatric DRESS. A single implicated drug was present in 262 cases, and drugs with 10 or more cases were included in this analysis (n = 224): carbamazepine (n = 86), dapsone (n = 16), lamotrigine (n = 25), phenobarbital (n = 38), phenytoin (n = 45) and trimethoprim-sulfamethoxazole (n = 14). Dapsone was associated with increased organ involvement, the highest mortality rate and the longest period of hospitalization. In addition, we showed that trimethoprim-sulfamethoxazole was associated with higher rates of autoimmune sequelae. This study confirms that drug-specific features exist and may impact the acute and long-term management of DRESS in children.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"408-411"},"PeriodicalIF":3.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatologist's role in managing cutaneous adverse events of anticancer drugs: a retrospective analysis of 538 hospital dermatology consultations in Japan.","authors":"Shohei Kitayama, Koji Katsuumi, Sumiko Takatsuka, Tadamichi Shimizu, Tatsuya Takenouchi","doi":"10.1093/ced/llae407","DOIUrl":"10.1093/ced/llae407","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"444-446"},"PeriodicalIF":3.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}